ReviewTranslational lung cancer research2013
Activated RET and ROS: two new driver mutations in lung adenocarcinoma.
Review in Translational lung cancer research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 16 citations in OpenAlex.
- Benefit-Risk Summary of Crizotinib for the Treatment of Patients With ROS1 Alteration-Positive, Metastatic Non-Small Cell Lung Cancer.The oncologist · 2016Trial
- Assessment of Exhaled Breath Condensate for ALK, RET, ROS1, and NTRK1 Fusion Transcript Detection in NSCLC: Comparison With Tissue and Liquid Biopsy Samples.Thoracic cancer · 2025Article
- [Immunohistochemistry-based predictive biomarkers for lung cancer].Der Pathologe · 2020Review
- Comparison of the genomic background of MET-altered carcinomas of the lung: biological differences and analogies.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2019Article
- Up-Regulated FGFR1 Expression as a Mediator of Intrinsic TKI Resistance in EGFR-Mutated NSCLC.Translational oncology · 2019Article
- Identifying gene-gene interactions using penalized tensor regression.Statistics in medicine · 2018Article
- Antitumor Activity of RXDX-105 in Multiple Cancer Types withClinical cancer research : an official journal of the American Association for Cancer Research · 2017Article
- Dysregulation of the Met pathway in non-small cell lung cancer: implications for drug targeting and resistance.Translational lung cancer research · 2015Review
- Efficacy of third-line pemetrexed monotherapy versus pemetrexed combination with bevacizumab in patients with advanced EGFR mutation-positive lung adenocarcinoma.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2014Article
- [Advances of driver gene and targeted therapy of non-small cell lung cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2014Review
- Genomic Profiling Reveals Medullary Thyroid Cancer Misdiagnosed as Lung Cancer.Case reports in oncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rearrangements of ROS1 and RET have been recently described as new driver mutations in lung adenocarcinoma with a frequency of about 1% each. RET and ROS1 rearrangements both represent unique molecular subsets of lung adenocarcinoma with virtually no overlap with other known driver mutations described so far in lung adenocarcinoma. Specific clinicopathologic characteristics have been described and several multitargeted receptor kinase inhibitors have shown in vitro activity against NSCLC cells harbouring these genetic alterations. In addition, the MET/ALK/ROS inhibitor crizotinib has already shown impressive clinical activity in patients with advanced ROS1-positive lung cancer. Currently, several early proof of concept clinical trials are testing various kinase inhibitors in both molecular subsets of lung adenocarcinoma patients. Most probably, personalized treatment of these genetically defined new subsets of lung adenocarcinoma will be implemented in routine clinical care of lung cancer patients in the near future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.